NCT06739980 - The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency | Biotech Hunter

Timeline

Start Date

January 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions

Ectonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyAutosomal Recessive Hypophosphatemic RicketsGeneralized Arterial Calcification of Infancy 1

Interventions

DRUG

INZ-701

Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.